Questions and Answers
Which of the following is characterized by macrovesicular hepatic steatosis and mild inflammation?
What level of alcohol consumption is considered heavy for women?
Which patient group is considered to have higher risk for liver-related events in NASH?
What is not recommended for general population-based screening for NAFLD?
Signup and view all the answers
What should be monitored if FIB-4 is less than 1.3 in patients with T2DM?
Signup and view all the answers
What should be given to patients with triglyceride concentrations over 500 mg/dL?
Signup and view all the answers
Which substance has been found to particularly increase the risk of NAFLD, NASH, and advanced fibrosis?
Signup and view all the answers
What medication is currently approved for the treatment of NASH?
Signup and view all the answers
Which of the following treatments does not offer a meaningful histological benefit in NASH?
Signup and view all the answers
What is the recommended frequency for testing children and young people for NAFLD who have type 2 diabetes or metabolic syndrome and have a normal ultrasound?
Signup and view all the answers
What should be considered for adults with advanced liver fibrosis in secondary or tertiary care settings?
Signup and view all the answers
What is the ELF score threshold indicating unlikely advanced liver fibrosis?
Signup and view all the answers
How often should adults reassess for advanced liver fibrosis if they have an ELF score below 10.51?
Signup and view all the answers
What is NOT recommended for assessing advanced liver fibrosis in people with NAFLD?
Signup and view all the answers
What should be explained to individuals with an ELF score above 10.51?
Signup and view all the answers
Which of the following individuals should be considered for retesting regarding advanced liver fibrosis every 2 years?
Signup and view all the answers
What condition contraindicates the use of pioglitazone?
Signup and view all the answers
What is the primary condition that should prompt a liver ultrasound testing for children and young people?
Signup and view all the answers
What is the recommended interval for monitoring children and young people with NAFLD who have an ELF score below 10.51?
Signup and view all the answers
Which of the following statements is true regarding routine liver blood tests for assessing advanced liver fibrosis in NAFLD?
Signup and view all the answers
What is the recommended management for adults with advanced liver fibrosis without diabetes?
Signup and view all the answers
What criterion must be met for an ELF score to indicate the likelihood of advanced liver fibrosis?
Signup and view all the answers
At what frequency should adults with an ELF score below 10.51 undergo reassessment for advanced liver fibrosis?
Signup and view all the answers
Which dietary supplement is NOT recommended for adults with NAFLD?
Signup and view all the answers
In what scenario is pioglitazone contraindicated?
Signup and view all the answers
What histological finding may no longer be fully appreciated in a liver biopsy of patients with cirrhosis?
Signup and view all the answers
What is the primary risk assessment tool indicated for assessing liver fibrosis?
Signup and view all the answers
What is the relationship between excessive fructose consumption and liver disease?
Signup and view all the answers
In patients with elevated triglyceride concentrations of 200 mg/dL or higher, what medication combination is recommended?
Signup and view all the answers
What liver-related condition is often linked to genetic polymorphisms?
Signup and view all the answers
What should individuals with clinically significant hepatic fibrosis (≥ F2) completely abstain from?
Signup and view all the answers
What is the minimum frequency for monitoring FIB-4 in patients without T2DM?
Signup and view all the answers
Is coffee consumption recommended for individuals with liver disease?
Signup and view all the answers
What notable condition is associated with patients with NASH and increased fibrosis risk?
Signup and view all the answers
Which treatment has yet to receive approval for NASH?
Signup and view all the answers
Study Notes
Non-Alcoholic Fatty Liver Disease (NAFLD)
- Commonly associated with type 2 diabetes mellitus (T2DM) and metabolic syndrome.
- Liver ultrasound should be offered to children and young adults with T2DM or metabolic syndrome who do not misuse alcohol.
- Testing frequency for NAFLD in children and young people with normal ultrasound results, T2DM, or metabolic syndrome is every 3 years.
Assessment Tools & Monitoring
- Use Enhanced Liver Fibrosis (ELF) score to assess advanced liver fibrosis in NAFLD patients.
- Routine liver blood tests are not recommended for assessing advanced liver fibrosis.
- An ELF score of 10.51 or above indicates advanced liver fibrosis; below this score suggests low risk.
- Reassessment for advanced liver fibrosis should be every 3 years for adults and every 2 years for children and young people with an ELF score below 10.51.
Treatment Considerations
- Omega-3 fatty acids are not recommended for adults with NAFLD.
- In secondary or tertiary care, pioglitazone or vitamin E may be considered for adults with advanced liver fibrosis, regardless of diabetes status.
- Pioglitazone is contraindicated in patients with a history of heart failure, bladder cancer, or macroscopic hematuria.
- Only in tertiary care, vitamin E should be considered for children with advanced liver fibrosis.
NAFLD Subtypes & Progression
- NAFL characterized by macrovesicular hepatic steatosis with mild inflammation.
- NASH involves inflammation and cellular injury (ballooning) and may have fibrosis.
- Cirrhosis features fibrous septa and cirrhotic nodules; earlier NASH symptoms may be less visible on biopsy.
Risks & Screening
- Most common causes of death in NAFLD patients are cardiovascular disease (CVD) and nonhepatic malignancies.
- Patients with NASH and F2-4 fibrosis are categorized as “at-risk” for liver-related complications.
- Heavy alcohol consumption is defined as ≥40 g for women and ≥60 g for men.
- Patients with significant hepatic fibrosis (≥ F2) should completely abstain from alcohol.
General Screening & Risk Assessment
- General population-based screening for NAFLD is not advised.
- The Fibrosis 4 (FIB-4) index is utilized for primary risk assessment; FIB-4 less than 1.3 suggests further monitoring.
- FIB-4 should be reevaluated every 1-2 years for those with T2DM or metabolic risk factors; otherwise, every 2-3 years.
Additional Risk Management
- Fibrates or combinations with prescription-grade omega-3s are recommended for triglyceride levels ≥500 mg/dL to mitigate pancreatitis risks and potentially improve CVD outcomes.
- Excessive fructose intake raises the risk of NAFLD, NASH, and advanced fibrosis independently of total calorie intake.
- Coffee consumption may be beneficial; drinking 3 or more cups per day is advisable without contraindications.
Treatment Approvals & Ineffective Therapies
- Pioglitazone is approved for NASH treatment; GLP-1 receptor agonists are not yet approved.
- The following medications are ineffective in providing meaningful histological benefits for NASH: Metformin, Urosdeoxycholic acid, Dipeptidyl peptidase 4 inhibitors, Statins, and Silymarin.
Non-Alcoholic Fatty Liver Disease (NAFLD)
- Commonly associated with type 2 diabetes mellitus (T2DM) and metabolic syndrome.
- Liver ultrasound should be offered to children and young adults with T2DM or metabolic syndrome who do not misuse alcohol.
- Testing frequency for NAFLD in children and young people with normal ultrasound results, T2DM, or metabolic syndrome is every 3 years.
Assessment Tools & Monitoring
- Use Enhanced Liver Fibrosis (ELF) score to assess advanced liver fibrosis in NAFLD patients.
- Routine liver blood tests are not recommended for assessing advanced liver fibrosis.
- An ELF score of 10.51 or above indicates advanced liver fibrosis; below this score suggests low risk.
- Reassessment for advanced liver fibrosis should be every 3 years for adults and every 2 years for children and young people with an ELF score below 10.51.
Treatment Considerations
- Omega-3 fatty acids are not recommended for adults with NAFLD.
- In secondary or tertiary care, pioglitazone or vitamin E may be considered for adults with advanced liver fibrosis, regardless of diabetes status.
- Pioglitazone is contraindicated in patients with a history of heart failure, bladder cancer, or macroscopic hematuria.
- Only in tertiary care, vitamin E should be considered for children with advanced liver fibrosis.
NAFLD Subtypes & Progression
- NAFL characterized by macrovesicular hepatic steatosis with mild inflammation.
- NASH involves inflammation and cellular injury (ballooning) and may have fibrosis.
- Cirrhosis features fibrous septa and cirrhotic nodules; earlier NASH symptoms may be less visible on biopsy.
Risks & Screening
- Most common causes of death in NAFLD patients are cardiovascular disease (CVD) and nonhepatic malignancies.
- Patients with NASH and F2-4 fibrosis are categorized as “at-risk” for liver-related complications.
- Heavy alcohol consumption is defined as ≥40 g for women and ≥60 g for men.
- Patients with significant hepatic fibrosis (≥ F2) should completely abstain from alcohol.
General Screening & Risk Assessment
- General population-based screening for NAFLD is not advised.
- The Fibrosis 4 (FIB-4) index is utilized for primary risk assessment; FIB-4 less than 1.3 suggests further monitoring.
- FIB-4 should be reevaluated every 1-2 years for those with T2DM or metabolic risk factors; otherwise, every 2-3 years.
Additional Risk Management
- Fibrates or combinations with prescription-grade omega-3s are recommended for triglyceride levels ≥500 mg/dL to mitigate pancreatitis risks and potentially improve CVD outcomes.
- Excessive fructose intake raises the risk of NAFLD, NASH, and advanced fibrosis independently of total calorie intake.
- Coffee consumption may be beneficial; drinking 3 or more cups per day is advisable without contraindications.
Treatment Approvals & Ineffective Therapies
- Pioglitazone is approved for NASH treatment; GLP-1 receptor agonists are not yet approved.
- The following medications are ineffective in providing meaningful histological benefits for NASH: Metformin, Urosdeoxycholic acid, Dipeptidyl peptidase 4 inhibitors, Statins, and Silymarin.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
This quiz explores non-alcoholic fatty liver disease (NAFLD), its association with type 2 diabetes, and metabolic syndrome. It also discusses recommendations for liver ultrasound testing in children and young people at risk. Test your understanding of NAFLD diagnosis and monitoring protocols.
